Cantor Fitzgerald reiterates Trulieve Cannabis stock Overweight rating

Cantor Fitzgerald reiterated an Overweight rating and $15.00 price target on Trulieve Cannabis (TRLV), citing its scaled, vertically integrated medical operations. The stock is up 43% over six months, trading at $10.92. Q2 2026 earnings beat estimates with $0.11 EPS, though revenue slightly missed at $271M. The firm noted the company's organized, scalable platform and expects profitability this year.

Original reporting
Published Oct 23, 2026, 12:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TRLV
Bullish
high confidence
Mentioned
$TRLV
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TRLVBullishMed
01

Why it matters

The earnings beat and analyst reaffirmation could attract new buying, but revenue miss and regulatory headwinds temper enthusiasm.

02

Market read

The article provides fresh earnings data and analyst rating, offering a medium‑term trade idea for TRLV.

03

What to watch

Potential regulatory risk from the DEA's pause on cannabis rescheduling could affect future growth.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Trulieve recently uplisted to the NYSE and completed a strategic restructuring. The DEA has paused cannabis rescheduling hearings, adding regulatory uncertainty.

Company-level read

Ticker impact

$TRLVBullishHigh confidence
Context

Cantor Fitzgerald reiterated an Overweight rating with a $15 price target and reported Trulieve's Q2 earnings beat expectations at $0.11 EPS versus $0.08 consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat and higher target.

Evidence & confidence

The combination of a fresh earnings beat and a maintained Overweight rating with a higher price target provides a clear catalyst for buying interest.

Market effects

Positive for the U.S. medical cannabis sector as the first NYSE‑listed cannabis company shows profitability.

May boost investor sentiment toward Florida‑based cannabis operators.

Limited to cannabis niche; no broad market impact.

Counterpoint

The earnings beat was modest and revenue missed; the stock may be overvalued relative to fair value.

Key entities

  • Trulieve Cannabis Corp.

    U.S. medical cannabis operator, ticker TRLV.

  • Cantor Fitzgerald

    Equity research firm reiterating Overweight rating.

Related articles

$TRLVHigh

Trulieve (TRLV) Q3 2026 Earnings Call Transcript

Trulieve (TRLV) reported Q3 2026 earnings exceeding guidance, with $230M revenue (4% YoY growth), 64% gross margin, and $89M adjusted EBITDA. The company benefited from federal rescheduling of medical marijuana to Schedule III, enabling DEA registration, tax relief, and NYSE listing. Trulieve also repaid $65M in debt, improving cash flow. The company is expanding in Georgia and Texas, with strategic initiatives focused on access, growth, and product portfolio.

$TRLVHigh

Trulieve Reports Third Quarter 2026 Results

Trulieve Cannabis Corp. (TRLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Trulieve Reports Third Quarter 2026 Results • Third quarter revenue of $230 million, with 64% gross margin • Cash flow from operations of $183 million and free cash flow of $120 million* in first nine months of 2026 • Received final DEA registrations pursuant to fina

High

Federal drug officials register Trulieve's medical marijuana dispensaries

Trulieve Cannabis Corp. reported Q3 2026 revenue of $230 million, with a 64% gross margin. The company received final DEA registrations for its medical marijuana dispensaries following the rescheduling of cannabis to Schedule III. Trulieve also repaid $65 million in mortgage notes and operates 208 retail dispensaries. CEO Kim Rivers highlighted milestones unlocked by the rescheduling, including tax benefits and NYSE listing.